10.03.19
Frontage Laboratories, Inc., a contract research organization, is expanding its bioanalytical laboratories in the U.S. in Exton, PA to include an additional 10,000 square feet of lab space dedicated to further enhancing capabilities in biologic drug development, biomarkers and cell and gene therapy.
A center of excellence supporting cell and gene therapy will be established which will include dedicated labs in DNA separation, purification, flow cytometry, and cell culture. In addition, the expansion will provide greater biomarker, PK, and immunogenicity bioanalytical capacity to support large Phase II-IV studies.
As part of the expansion, support services will also be enhanced including sample management and sample storage space. LC-MS/MS and ICP-MS instrument capacity will also be expanded to support both large and small molecule, and elemental analysis. The expansion is scheduled for completion in 4Q19.
According to Dr. John Lin, Ph.D., executive vice president, Frontage Global Bioanalytical Services, “The expansion will provide our customers with enhanced bioanalytical capacity to support their large-scale clinical trials. This investment will allow us to enhance our support for new therapeutic platforms such as cell and gene therapy.”
A center of excellence supporting cell and gene therapy will be established which will include dedicated labs in DNA separation, purification, flow cytometry, and cell culture. In addition, the expansion will provide greater biomarker, PK, and immunogenicity bioanalytical capacity to support large Phase II-IV studies.
As part of the expansion, support services will also be enhanced including sample management and sample storage space. LC-MS/MS and ICP-MS instrument capacity will also be expanded to support both large and small molecule, and elemental analysis. The expansion is scheduled for completion in 4Q19.
According to Dr. John Lin, Ph.D., executive vice president, Frontage Global Bioanalytical Services, “The expansion will provide our customers with enhanced bioanalytical capacity to support their large-scale clinical trials. This investment will allow us to enhance our support for new therapeutic platforms such as cell and gene therapy.”
